



# Q3 2024 Financial Results

# Appendix

# Anylam Pharmaceuticals, Inc.

## Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands, except per share amounts)

	Three Months Ended	
	September 30, 2024	September 30, 2023
<b>Reconciliation of GAAP to Non-GAAP Research and development:</b>		
GAAP Research and development	\$ 270,926	\$ 253,179
Less: Stock-based compensation expenses	(19,794)	(29,155)
Non-GAAP Research and development	<u>\$ 251,132</u>	<u>\$ 224,024</u>
<b>Reconciliation of GAAP to Non-GAAP Selling, general and administrative:</b>		
GAAP Selling, general and administrative	\$ 220,993	\$ 199,175
Less: Stock-based compensation expenses	(26,010)	(34,782)
Non-GAAP Selling, general and administrative	<u>\$ 194,983</u>	<u>\$ 164,393</u>
<b>Reconciliation of GAAP to Non-GAAP Operating (loss) income:</b>		
GAAP Operating (loss) income	\$ (76,905)	\$ 213,867
Add: Stock-based compensation expenses	45,804	63,937
Non-GAAP Operating (loss) income	<u>\$ (31,101)</u>	<u>\$ 277,804</u>



# Anylam Pharmaceuticals, Inc.

## Reconciliation of Revenue and Growth at Constant Currency

	<b>September 30, 2024</b>
	<b>Three Months Ended</b>
Total TTR net product revenue growth, as reported	34 %
Add: Impact of foreign currency translation	1
Total TTR net product revenue growth at constant currency	<u>35 %</u>
Total Rare net product revenue growth, as reported	34 %
Add: Impact of foreign currency translation	—
Total Rare net product revenue growth at constant currency	<u>34 %</u>
Total net product revenue growth, as reported	34 %
Add: Impact of foreign currency translation	1
Total net product revenue growth at constant currency	<u>35 %</u>
Total revenue growth, as reported	(33)%
Add: Impact of foreign currency translation	—
Total revenue growth at constant currency	<u>(33)%</u>